Medtronic plc announced the U.S. commercial launch of its MiniMed 630G system with SmartGuard technology FDA approved for the treatment of people with diabetes mellitus sixteen years of age and older. The MiniMed 630G features a new insulin pump hardware platform that combines personalized diabetes management with clinical performance. The MiniMed 630G system is the newest member of the MiniMed family.
The user-friendly pump design is waterproof, has remote bolus functionality, and features a high-definition, full-color screen that supports easy navigation and enables increased customization.
The MiniMed 630G system uses the Contour Next Link 2.4 blood glucose meter from Ascensia Diabetes Care to provide blood glucose test results that have been shown to be highly accurate. The meter automatically transmits blood glucose results to calculate boluses using the Bolus Wizard calculator and to calibrate the CGM sensor, which helps prevent manual entry errors. It also allows patients to discreetly give themselves a bolus of insulin remotely from the meter.
The MiniMed 630G system combines its proprietary SmartGuard technology featured in the MiniMed 530G system with a brand new user-friendly design. The new pump platform fully integrates continuous glucose monitoring (CGM) and SmartGuard technology, which is designed to trigger an alarm when the CGM sensor glucose level reaches a preset low threshold and suspends insulin delivery if the user is unresponsive to the alarm.
“Low blood sugar at night is of particular concern, when up to 75 percent of severe hypoglycemia occurs and patients are unlikely to be aware of symptoms while they are asleep,” said Satish Garg, M.D., Editor-in-Chief of Diabetes Technology and therapeutics and professor of pediatrics and medicine and director of the adult diabetes program at the University of Colorado Denver, Barbara Davis Center for Childhood Diabetes. “The ability to automate the suspension of insulin at night is an important feature as prolonged hypoglycemia could be life-threatening.”
